换一批
换一批Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼酸化物(Boronic Acids);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);吡嗪类(Pyrazines);沙立度胺(Thalidomide);治疗失败(Treatment Failure);治疗结果(Treatment Outcome)
DOI
10.1182/blood-2012-08-450742
PMID
23243282
发布时间
2022-04-08
- 浏览3
Blood
1961-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
